08 nov: Langsigtet incitamentsprogram
08 nov: Offentliggørelse af det individuelle solvensbehov
08-11-2017 17:01:17

Genmab Announces Financial Results for the First Nine Months of 2017

Relateret indhold
20 jun - 
Onsdagens aktier: Rekord-Ambu satte C25 til vægs
20 jun - 
Aktier/middag: Ambu sætter fart på med uforklaret stign..
20 jun - 
Aktier/åbning: Udlandet løfter Ambu i rekord - Genmab g..
Relateret debat
08:05 - 
Teknisk skal den forbi 1020 før den hos mig bliver spæn..
05:47 - 
Jeg skriver jo netop også, at det ikke er rettet specif..
20 jun - 
Tror vi banker igennem 1040 imorgen.

November 8, 2017; Copenhagen, Denmark;

Interim Report for the First Nine Months Ended September 30, 2017

Highlights

  • USD 871 million in net sales of DARZALEX® (daratumumab); resulting in royalty income of DKK 707 million

  • DARZALEX approved for relapsed or refractory multiple myeloma in Japan

  • Announced positive topline results in Phase III ALCYONE study of daratumumab in front line multiple myeloma

  • Seattle Genetics exercised its option to co-develop tisotumab vedotin with Genmab

“This past quarter we continued to focus on progressing our innovative antibody pipeline.  DARZALEX received its first approval in Japan, for the treatment of relapsed or refractory multiple myeloma.  We also reported exciting data from the Phase III ALCYONE study of daratumumab in front line multiple myeloma.  Finally, we were pleased to announce that Seattle Genetics exercised its option to co-develop tisotumab vedotin and we very much look forward to our collaboration to rapidly bring this product into the next stages of clinical evaluation,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Financial Performance First Nine Months of 2017

  • Revenue was DKK 1,348 million in the first nine months of 2017 compared to DKK 889 million in the first nine months of 2016. The increase of DKK 459 million, or 52%, was mainly driven by higher DARZALEX royalties and milestones.

  • Operating expenses were DKK 707 million in the first nine months of 2017 compared to DKK 544 million in the first nine months of 2016. The increase of DKK 163 million, or 30%, was due to the additional investment in our pipeline of products, including the advancement of tisotumab vedotin,  HexaBody®-DR5/DR5, DuoBody®-CD3xCD20, and other products in our pipeline.

  • Operating income was DKK 641 million in the first nine months of 2017 compared to DKK 345 million in the first nine months of 2016.  The increase of DKK 296 million, or 86%, was driven by higher revenue, which was partly offset by increased operating expenses in 2017.

  • On September 30, 2017, Genmab had a cash position of DKK 5,184 million compared to DKK 3,922 million at December 31, 2016. This represented a net increase of DKK 1,262 million, which was mainly driven by positive working capital adjustments of DKK 575 million related to milestones achieved in the fourth quarter of 2016 that were received in 2017, our operating income of DKK 641 million, and proceeds from the exercise of warrants of DKK 208 million.

Outlook                                                                                          

Genmab is maintaining its 2017 financial guidance published on February 22, 2017 and reiterated on September 27, 2017.

Conference Call

Genmab will hold a conference call in English to discuss the results for the first nine months of 2017 today, Wednesday, November 8, at 6.00 pm CET, 5.00 pm GMT or 12.00 pm EDT. The dial in numbers are:

+1 646 254 3360 (US participants) and ask for the Genmab conference call

+44 20 3427 1910 (international participants) and ask for the Genmab conference call

 

A live and archived webcast of the call and relevant slides will be available at www.genmab.com.

Contact:         

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

The interim report contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the section “Risk Management” in Genmab’s annual report, which is available on www.genmab.com and the “Significant Risks and Uncertainties” section in the interim report. Genmab does not undertake any obligation to update or revise forward looking statements in this interim report nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Download the full Interim Report for the first nine months of 2017 on attachment or at www.genmab.com.

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

 

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

 

 

Vedhæftet fil: Q3 2017 Interim Report.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 jun
GEN
Et gammelt indlæg:   Hvis man kigger lidt tilbage i tiden og ser på de kvartalsvise resultater, så l..
34
20 jun
GEN
Hold da kæft, du er godt nok en sur (gammel ?) mand......
9
20 jun
GEN
Som altid dejlig at læse dine indlæg, der er ikke så meget hokus pokus, og du ved hvad du snakker om..
6
20 jun
GEN
Det er FA der er igang. Ingen tvivl om der snart kommer en opjustering. Med salg +500 mil usd i Q2 e..
5
20 jun
GEN
Op med humøret TheNote Den skal nok falde igen på et tidspunkt så kan du holde en fest.
4
16 jun
GEN
På proinvestor findes en gruppe personer, der har sat sig rigtig godt ind i casen og følger GEN tæt...
4
20 jun
GEN
Jeg ville ogsaa lukke short positioner hvis jeg var short i Genmab. Tror du Har ret I det er det der..
3
20 jun
GEN
Du er jo en gnavpot. Tabt på gen??
3
20 jun
GEN
På den lange bane ser jeg Genmab som en aktie der kommer til at stige og stige . Den sikreste invest..
3
20 jun
GEN
Tak for opsummeringen Sukkeralf. Som altid en fornøjelse at læse dine indlæg. Både her og på Proinve..
3

Jyske Bank/CEO: Vi satser meget, meget hårdt på it - citat

20-06-2018 13:38:15
Jyske Bank vil i løbet af 2018 blive en forandret bank, hvilket vil været drevet af store investeringer i optimeringer. Det skal ske gennem hvad bankens ordførende direktør, Anders Dam, i et interview med Finanswatch kalder "robotisering". For nylig fik banken sine kapitalforhold på plads efter salget af sin 38,5 pct. ejerandel i Nordjyske Bank.- Nu er det endt der, hvor vi har fået løst vores kap..

Ambu: Udenlandske investorer sender aktien mod rekord

20-06-2018 11:18:25
Der er rift om Ambu onsdag formiddag, hvor aktien har sat kursen mod rekord efter en gevinst, der bare har vokset sig større og større i løbet af formiddagen.En rundringning til et par handlere og analytikere har umiddelbart ikke kastet en forklaring af sig.- Der er ingen nyheder ude om Ambu, og vi sidder umiddelbart også og undrer os lidt, siger chefhandler i Danske Bank Mads Zink til Ritzau Fina..

Aktier/tendens: Comeback i sigte - salgstal kan løfte Genmab

20-06-2018 08:30:13
En løftet anbefaling og lovende salgstal fra USA kan løfte Genmab fra åbningen onsdag, hvor udsigterne er noget lysere, end da handlerne slukkede for deres skærme tirsdag eftermiddag.De amerikanske aktier faldt godt nok tirsdag, efter at USA og Kina havde udvekslet nye toldafgifter, men markedet rettede sig noget efter dansk børslukketid, og onsdag morgen peger S&P 500-futuren på en positiv åbning..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/åbning: Udlandet løfter Ambu i rekord - Genmab går til tops
2
Onsdagens aktier: Rekord-Ambu satte C25 til vægs
3
Aktier/middag: Ambu sætter fart på med uforklaret stigning
4
MHI Vestas/CEO: Skal udvikle os uden at "disrupte" værdikæden
5
Pandora: Kapitalfond tror mindre på kursfald

Relaterede aktiekurser

Genmab A/S 1.014,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. juni 2018 08:48:22
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB3 - 2018-06-21 08:48:22 - 2018-06-21 08:48:22 - 1 - Website: OKAY